12results about How to "Low hemolytic" patented technology

The invention belongs to the technical field of biological medicines, and relates to an antibacterial polypeptide, a composition and application thereof. The amino acid sequence of the antibacterial polypeptide is as shown in SEQ ID NO. 1: KWKIKWPVKWFKM-NH2. The invention also discloses a preparation method of the antibacterial polypeptide. Experiments show that the antibacterial polypeptide disclosed by the invention has broad-spectrum antibacterial activity on gram-positive bacteria and / or gram-negative bacteria, and also has low cytotoxicity and low hemolysis. The antibacterial polypeptide provided by the invention consists of 14 amino acids, is relatively short in peptide chain, small in molecular weight and easy to artificially synthesize, is a micromolecular polypeptide with extremely high application value, can be used for preparing a novel antibacterial agent, and has a wide application prospect.

The invention discloses an antibacterial peptide and application thereof. The antibacterial peptide comprises one or more of an antibacterial peptide PFK with an amino acid sequence as shown in SEQ ID NO: 1, an antibacterial peptide PVK with an amino acid sequence as shown in SEQ ID NO: 2 and an antibacterial peptide PIK with an amino acid sequence as shown in SEQ ID NO: 3. The antibacterial peptides PFK, PVK and PIK disclosed by the invention have antibacterial effects on porphyromonas gingivalis, streptococcus mutans, acinetobacter baumannii, escherichia coli and staphylococcus aureus, and the antibacterial peptides PFK, PVK and PIK have relatively low hemolytic activity and relatively low cytotoxicity, so that the antibacterial peptides PFK, PVK and PIK can be used for preparing biological antibacterial preparations, anti-infection drugs or oral products.

The present invention discloses an antimicrobial peptide and its application, wherein the antimicrobial peptide comprises one or more of an antimicrobial peptide PFK having an amino acid sequence as shown in SEQ ID NO: 1, an antimicrobial peptide PVK having an amino acid sequence as shown in SEQ ID NO: 2, and an antimicrobial peptide PIK having an amino acid sequence as shown in SEQ ID NO: 3. The antimicrobial peptides PFK, PVK and PIK of the present invention have antimicrobial effects on Porphyromonas gingivalis, Streptococcus mutans, Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and the antimicrobial peptides PFK, PVK and PIK have low hemolytic activity and low cytotoxicity, and can be used to prepare biological antimicrobial preparations, anti-infective drugs or oral products.

The invention discloses an OVA (at) MMSNs (at) BM-Mannose bionic nano vaccine and a preparation method thereof, and belongs to the technical field of nano vaccines. The OVA (at) MMSNs (at) BM-Mann rose bionic nano vaccine is a nano material coated by a bacterial plasma membrane. The OVA (at) MMSNs (at) BM-Mannose bionic nano vaccine prepared by the preparation method disclosed by the invention is strong in cellular uptake ability and good in storage stability; the hemolytic activity is low, and the hemolysis rate of 6% or below can still be kept even when the concentration is 100 micrograms per milliliter; the in-vitro cytotoxicity is small, and the safety is high; obvious toxicity is not generated on mice in vivo; the hydration particle size is 220nm; dC2.4 cells have the phenomena of continuous uptake and concentration dependence on the nano vaccine, are basically saturated within 2 hours, and have the potential of being applied to the field of magnetic resonance imaging; the activation efficiency on DC2.4 is high; the targeting delivery capability is realized; according to the prepared FITC-OVA (at) MMS Ns (at) BM-Mannose bionic nano vaccine, the visual delivery of the nano vaccine can be realized, and the observation and research are convenient; the preparation method of the bionic nano vaccine is simple and easy to operate, and the used raw materials are safe, non-toxic or low in toxicity and safe to the environment and operators.

The invention discloses a low hemolytic cationic lipid-cholesterol monoguanidine conjugate and a preparation method of the low hemolytic cationic lipid-cholesterol monoguanidine conjugate. The cholesterol monoguanidine conjugate has the characteristic of low hemolysis rate, can be used for constructing preparations needing positive ions, such as lipid nanoparticles or lipidosome and the like, and has the potential of being used as an excellent auxiliary material.

The invention discloses an antibacterial peptide as well as a preparation method and application thereof. The amino acid sequence of the antibacterial peptide is LKVVFKVLFKRRR. The antibacterial peptide disclosed by the invention has relatively excellent antibacterial activity and metabolic stability and relatively low hemolytic activity and cytotoxicity, and is expected to become a novel antibacterial candidate drug. In addition, the antibacterial peptide is short in polypeptide sequence and only contains 13 amino acids, and all the amino acids are L-type amino acids, so that the antibacterial peptide is convenient to produce, low in production cost and beneficial to application and popularization. Generally speaking, the antibacterial peptide provided by the invention lays a foundation for further development of novel antibacterial drugs.

The application discloses an antibacterial peptide designed by a generative artificial intelligence framework and targeting gram-negative bacteria and an application thereof, and belongs to the fields of artificial intelligence and biotechnology. The application designs and successfully obtains a novel antibacterial peptide by a generative artificial intelligence framework, the antibacterial peptide targeting gram-negative bacteria and having good antibacterial activity. It is verified by experiments that the antibacterial peptide MTAMP003 has good bacteriostatic capacity on E. coli, S. typhimurium, P. aeruginosa and A. baumannii, exhibits low cytotoxicity on human gastric mucosa epithelium and low hemolyticity on rabbit red blood cells, and has good application prospect and research value.

The invention provides an antibacterial peptide for resisting acinetobacter baumannii, which is a) a polypeptide with an amino acid sequence of SEQ ID NO: 1 (KRIXRRIXIFLR), or b) a derivative peptide obtained by replacing and / or deleting and / or adding 1-5 amino acid residues on the polypeptide with the amino acid sequence of SEQ ID NO: 1, wherein X is Fmoc-S < 5 >-OH total hydrocarbon stapled amino acid. The invention also provides a preparation method and application of the antibacterial peptide. The protease degradation tolerant derivative is screened out through total hydrocarbon stapled amino acid replacement and structure-effect relationship research, and the protease degradation tolerant derivative is easy to prepare, high in biological safety and good in clinical application prospect.

The invention provides Buforin llb or a derivative peptide thereof as an ARF6 inhibitor and application. One purpose of the present application is to provide an ARF6 inhibitor comprising: (1) a peptide capable of binding to ARF6; (2) a nucleic acid molecule encoding the peptide; or (3) a biological material containing the peptide or nucleic acid molecule; the peptide is buforin IIb or a derivative peptide of the buforin IIb, and the buforin IIb or the derivative peptide of the buforin IIb can be combined with ARF6. The amino acid sequence of the buforin IIb is as shown in SEQ ID NO.1, the derivative peptides comprise derivative peptides B1 to B3 and derivative peptides C1 to C4, and the amino acid sequences of the derivative peptides B1 to B3 and the derivative peptides C1 to C4 are as shown in SEQ ID NO.2 to SEQ ID NO.8. The Buforin IIb or the derivative peptide thereof can be used as an ARF6 polypeptide inhibitor, and the polypeptide inhibitor provided by the invention has higher targeting property and is not easy to accumulate in vivo.

The invention relates to the technical field of vaccine adjuvants and drug delivery, and discloses a 3D-MLA and QS-21 composite adjuvant as well as a preparation method and application of the 3D-MLA and QS-21 composite adjuvant. A saponin QS-21; polyethylene glycol sodium alginate; embedding particles with pH-sensitive calcium chloride; the preparation method of the vaccine antigen comprises the following steps: performing pegylation modification on sodium alginate; embedding calcium chloride with a pH sensitive polymer, and carrying out spray drying to prepare cross-linking agent particles; dissolving the synthetic monophosphoryl lipid A and saponin QS-21 to prepare a composite adjuvant solution; mixing the adjuvant solution with the pegylated sodium alginate solution to prepare a precursor preparation; and adding antigen and cross-linking agent particles into the precursor preparation, and uniformly mixing to obtain a final product. According to the invention, the composite adjuvant is delivered through the pH responsive in-situ gel, an immune reservoir is formed, and a powerful and lasting comprehensive immune response biased to the Th1 type is safely induced.

The invention belongs to the technical field of biological medicines, and relates to a polypeptide, a composition and application of the polypeptide in preparation of antibacterial products. The amino acid sequence of the protein is as follows: KWMIKWPRKWFTVL. Experiments show that the polypeptide disclosed by the invention has broad-spectrum antibacterial activity on gram-positive bacteria and / or gram-negative bacteria, and also has low cytotoxicity and low hemolysis. The polypeptide provided by the invention consists of 14 amino acids, is relatively short in peptide chain, small in molecular weight and easy to artificially synthesize, is a micromolecular polypeptide with extremely high application value, can be used for preparing a novel antibacterial agent, and has a wide application prospect.

The invention relates to the technical field of agricultural biology, in particular to application of combination of licochalcone A and antibiotics in preparation of drugs for resisting clostridium perfringens. According to the invention, licochalcone A (LCA) is taken as a representative drug, the bacteriostatic action of the licochalcone A on clostridium perfringens when the licochalcone A is combined with various antibiotics is explored through a drug sensitive test, a sterilization curve, a hemolysis test, a sliding test and an infected mouse treatment test, and a clostridium perfringens resisting formula taking the LCA and the antibiotics (tilmicosin or tetracycline) as main drugs is provided. According to the formula, the inhibition effect on the clostridium perfringens can be remarkably enhanced, the hemolysis of the clostridium perfringens is inhibited, the inflammatory response level caused by the clostridium perfringens is reduced, and the damage of the clostridium perfringens to muscle tissues is reduced. Therefore, when the clostridium perfringens infection is treated, the tilmicosin or tetracycline is combined with the LCA to act, so that the dosage of the medicine can be effectively reduced, and the treatment effect is improved.